These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8106897)

  • 1. Neurohormonal response to ventricular failure: pharmacologic management.
    Pratt NG
    J Cardiovasc Nurs; 1993 Oct; 8(1):49-62. PubMed ID: 8106897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current role of digoxin in the treatment of heart failure.
    Smith JR; Gheorghiade M; Goldstein S
    Coron Artery Dis; 1993 Jan; 4(1):16-26. PubMed ID: 8269181
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurohumoral control mechanisms in congestive heart failure.
    Cohn JN; Levine TB; Francis GS; Goldsmith S
    Am Heart J; 1981 Sep; 102(3 Pt 2):509-14. PubMed ID: 6115571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.
    Coats AJ; Adamopoulos S
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):685-92. PubMed ID: 7873465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint.
    Williamson KM; Patterson JH
    Ann Pharmacother; 1997; 31(7-8):888-92. PubMed ID: 9220052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New trends in the use of angiotensin converting enzyme inhibitors in chronic heart failure.
    Massie BM
    Am J Med; 1988 Apr; 84(4A):36-46. PubMed ID: 3064607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
    Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
    Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in vasodilator therapy for heart failure.
    Cohn JN
    Am Heart J; 1991 Mar; 121(3 Pt 1):969-74. PubMed ID: 2000775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neurohormonal mechanisms in cardiac insufficiency. Possible therapeutic implications].
    Iannetti MV; Vallebona A; Perocchio M
    Minerva Cardioangiol; 1993 Mar; 41(3):81-9. PubMed ID: 8510813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic management of heart failure: neurohormonal agents.
    Moser DK
    Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
    Sigurdsson A; Swedberg K
    Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From digoxin to angiotensin-converting enzyme inhibitors: issues in pharmacotherapy for congestive heart failure.
    Hackenbruck HA
    Clin Excell Nurse Pract; 2000 Jul; 4(4):197-204. PubMed ID: 11261079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multifacetted role of angiotensin converting enzyme inhibitors in congestive heart failure.
    Firth BG
    Am J Med Sci; 1988 Oct; 296(4):275-88. PubMed ID: 3057910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin use in congestive heart failure. Current status.
    Riaz K; Forker AD
    Drugs; 1998 Jun; 55(6):747-58. PubMed ID: 9617590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
    Kinugawa T; Kato M; Mori M; Endo A; Kato T; Hamada T; Noguchi N; Omodani H; Osaki S; Ogino K; Miyakoda H; Hisatome I; Shigemasa C
    Eur J Clin Pharmacol; 1998 May; 54(3):209-14. PubMed ID: 9681661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored therapy to hemodynamic goals for advanced heart failure.
    Stevenson LW
    Eur J Heart Fail; 1999 Aug; 1(3):251-7. PubMed ID: 10935671
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurohormonal modulation in heart failure: ACE inhibition and beyond.
    Remme WJ
    Eur Heart J; 1995 Dec; 16 Suppl N():73-8. PubMed ID: 8682065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.